What's Happening?
Incyte has announced positive results from two Phase 1 studies of INCA033989, a mutant calreticulin-targeted monoclonal antibody, in patients with myelofibrosis (MF) and essential thrombocythemia (ET). The studies demonstrated that INCA033989 provides
rapid and durable clinical benefits, including significant spleen volume reductions, symptom improvement, and anemia responses. The drug was tested both as a monotherapy and in combination with ruxolitinib, showing a favorable safety profile with no dose-limiting toxicities. The findings were presented at the European Hematology Association 2026 Congress, highlighting the potential of INCA033989 to modify disease biology in MF and ET.
Why It's Important?
The development of INCA033989 is significant as it targets the underlying biology of myeloproliferative neoplasms, offering a potential new treatment for patients with CALR mutations who often respond poorly to existing therapies. This advancement could lead to improved disease management and quality of life for patients with MF and ET, conditions that currently lack targeted therapies. The drug's ability to deliver disease control while targeting the disease's biological drivers represents a promising step forward in the treatment of these blood cancers.
What's Next?
Incyte plans to initiate a pivotal study for essential thrombocythemia by mid-2026 and is engaging with regulators on a pivotal program for myelofibrosis. The company aims to advance INCA033989 into a Phase 3 study, which could pave the way for regulatory approval and broader clinical use. Continued collaboration with regulatory bodies and successful trial outcomes will be crucial for bringing this novel therapy to market.
